{"code":"PHA","name":"Pharmacy/Drug Stores","totalSpending":227124989.48000002,"totalFilings":7855,"yearlySpending":[{"year":2018,"income":26281627.48,"filings":1052},{"year":2019,"income":29259172,"filings":1134},{"year":2020,"income":32028000,"filings":1161},{"year":2021,"income":32870168,"filings":1053},{"year":2022,"income":36775836,"filings":1159},{"year":2024,"income":30310832,"filings":1055},{"year":2025,"income":39599354,"filings":1241}],"topClients":[{"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","income":7520000},{"name":"WALGREEN CO.","income":6140000},{"name":"CVS HEALTH","income":4250000},{"name":"ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY","income":3870000},{"name":"PHRMA","income":3032500},{"name":"HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.)","income":2560000},{"name":"CIGNA CORPORATION","income":2540000},{"name":"VIATRIS INC","income":2530000},{"name":"UNITEDHEALTH GROUP, INC.","income":2510000},{"name":"COMMUNITY ONCOLOGY ALLIANCE","income":2480000},{"name":"GENENTECH, INC.","income":2450000},{"name":"AMERICAN VETERINARY MEDICAL ASSOCIATION","income":2440000},{"name":"PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)","income":2375000},{"name":"THE CAMPAIGN FOR SUSTAINABLE RX PRICING","income":2370000},{"name":"HEALTHCARE DISTRIBUTION ALLIANCE","income":2370000},{"name":"NATIONAL ASSOCIATION OF CHAIN DRUG STORES","income":2250000},{"name":"ELI LILLY AND COMPANY","income":2200000},{"name":"AMERICA'S HEALTH INSURANCE PLANS","income":2180000},{"name":"CONSUMER HEALTHCARE PRODUCTS ASSOCIATION","income":2179529},{"name":"NEUROCRINE BIOSCIENCES, INC.","income":2120000},{"name":"TRAVERE THERAPEUTICS","income":2062500},{"name":"ALKERMES, INC.","income":2050000},{"name":"SK AMERICAS, INC.","income":1920000},{"name":"CVS HEALTH INC","income":1900000},{"name":"PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION","income":1830000},{"name":"NOVO NORDISK INC.","income":1830000},{"name":"TEVA PHARMACEUTICALS USA, INC.","income":1795000},{"name":"ALLIANCE FOR RURAL HOSPITAL ACCESS","income":1770000},{"name":"DYNAVAX TECHNOLOGIES","income":1700000},{"name":"AMERISOURCEBERGEN CORPORATION","income":1670000},{"name":"IQVIA","income":1640000},{"name":"BIOTECHNOLOGY INDUSTRY ORGANIZATION","income":1600000},{"name":"ASSOCIATION OF ACCESSIBLE MEDICINES","income":1580000},{"name":"CENTRIENT PHARMACEUTICALS LLC","income":1560000},{"name":"ASTRAZENECA PHARMACEUTICALS LP","income":1520000},{"name":"ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)","income":1510000},{"name":"CHILDREN'S NATIONAL MEDICAL CENTER","income":1400000},{"name":"ALVOGEN, PHARMA US, INC.","income":1400000},{"name":"340B HEALTH","income":1358500},{"name":"AMAG PHARMACEUTICAL","income":1335000},{"name":"ALLIANCE FOR PHARMACY COMPOUNDING","income":1320000},{"name":"CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION)","income":1320000},{"name":"DR. REDDY'S LABORATORIES, LTD","income":1305000},{"name":"BLUE SHIELD OF CALIFORNIA","income":1300000},{"name":"LILLY USA, LLC","income":1290000},{"name":"AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY)","income":1260000},{"name":"ASTRAZENECA","income":1210000},{"name":"PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION","income":1200000},{"name":"AMGEN USA INC.","income":1200000},{"name":"INDEPENDENT PHARMACY COOPERATIVE","income":1180000}],"topFirms":[{"name":"MEHLMAN CONSULTING, INC.","income":12640000},{"name":"TODD STRATEGY GROUP","income":10470000},{"name":"KOUNTOUPES DENHAM CARR & REID, LLC","income":7820000},{"name":"RUBICON ADVISORS, LLC","income":7220338},{"name":"BGR GOVERNMENT AFFAIRS","income":7190000},{"name":"TARPLIN, DOWNS & YOUNG, LLC","income":6410000},{"name":"MARSHALL & POPP, LLC","income":6220000},{"name":"FOLEY & LARDNER LLP","income":6020000},{"name":"FORBES-TATE","income":5020000},{"name":"BROWNSTEIN HYATT FARBER SCHRECK, LLP","income":4920000},{"name":"FARRAGUT PARTNERS LLP","income":4340000},{"name":"AKIN GUMP STRAUSS HAUER & FELD","income":3750000},{"name":"BALLARD PARTNERS","income":3050000},{"name":"PENN AVENUE PARTNERS","income":2960000},{"name":"RICCHETTI INCORPORATED","income":2880000},{"name":"INVARIANT LLC","income":2870000},{"name":"RED+BLUE STRATEGIES","income":2830000},{"name":"ACG ADVOCACY","income":2740000},{"name":"THE KPM GROUP DC LLC","income":2490000},{"name":"AMERICAN VETERINARY MEDICAL ASSOCIATION","income":2440000},{"name":"ALSTON & BIRD LLP","income":2320000},{"name":"BUCHANAN INGERSOLL & ROONEY PC","income":2310000},{"name":"FIERCE GOVERNMENT RELATIONS","income":2260000},{"name":"BOCKORNY GROUP, INC.","income":2220000},{"name":"ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)","income":2170000},{"name":"BLUESTONE STRATEGIES, LLC","income":2150000},{"name":"MCDERMOTT+ LLC","income":2130000},{"name":"HANCE SCARBOROUGH","income":2070000},{"name":"ARTEMIS POLICY GROUP LLC","income":2069000},{"name":"THORSEN FRENCH ADVOCACY LLC","income":2050000}],"sampleDescriptions":["Drug shortages and FDA approval.  USTR acceptance.","drug pricing, drug supply chain, opioid abuse epidemic, Medicare Part D","Controlled Substance act improvements. Opioid overdose death reduction. Alprazolam rescheduling.","Federal government relations service, strategy development and implementation relating to companys status of FDA action on NDA for oral testosterone.","Issues related to health insurance and prescription drug pricing.","Time-Temperature Indicators for Pharmaceuticals; and Drug Quality and Security Act","Issues relating to the regulations around drug manufacturing.","Drug FDA Approval: CAM2038","Federal government relations service, strategy development and implementation relating to status of FDAs action with regards to the companys NDA.","Federal government relations service, strategy development and implementation relating to regenerative medicine products.","Education and support for public policies that promote the development, use, coverage and reimbursement of novel, non-opioid pain therapies.","Issues relating to the regulation of PBMs and healthcare.","Medicare/Medicaid drug coverage, opioid addiction policy, S.2456 The CARA 2.0 Act of 2018.","CREATES Act, biosimilars regulation, drug pricing, intellectual property issues related to pharmaceuticals","Implementation of the Drug Quality and Security Act","Biodefense, Biomedical Advanced Research and Development Authority funding, vaccine research, development, manufacturing and marketing, infectious diseases, cancer, PAHPA, Labor-HHS Appropriations bil","Social Security, Healthcare","Addressing the high cost of pharmaceutical drugs","Issues related to the 340B drug discount program","Asthma policies and diagnostic test reimbursement. Drug shortage prevention and abuse-deterrent pseudophedrine."]}